I'm expecting
Reveal what LG paid us ?
LFT release shortly best in class ....
In talks potential partners ( queuing up they are IMHO )
Affyxell Daewoong update
Trials going extremely well and enough money to get us to significant inflection points ( in talks )
Nearly 12 Weeks and I'm expecting news this week best test avail Affidx .... Tesco's were selling like hot cakes today Chinese Shi-e
Tesco selling £2 a pop
https://www.tesco.com/groceries/en-GB/products/311680628?selectedUrl=https%3A%2F%2Fdigitalcontent.api.tesco.com%2Fv2%2Fmedia%2Fghs%2Fa67bd0b0-79c1-4473-b4db-78fe6e6e9988%2Fb607e1e2-14a6-4ef7-919e-f217ac098fb6_835868491.jpeg%3Fh%3D540%26w%3D540
Avacta's Diagnostics Division is developing an in-house pipeline of Affimer-based diagnostic assays, including the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test, and works with partners world-wide to develop bespoke Affimer® reagents for third party products.
Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. We note that hedge funds don't have a meaningful investment in Avacta Group. Jarvis Securities plc, Asset Management Arm is currently the company's largest shareholder with 7.4% of shares outstanding. In comparison, the second and third largest shareholders hold about 7.2% and 5.1% of the stock.
After doing some more digging, we found that the top 13 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company.
https://simplywall.st/stocks/gb/pharmaceuticals-biotech/aim-avct/avacta-group-shares/news/are-institutions-heavily-invested-in-avacta-group-plcs-lonav
In addition, under the clinical trial supervision of the Royal College of Surgeons, Ireland, 40 subjects, 16 of which were independently confirmed as COVID19 positive with PCRiii tests, provided breath samples that were tested on the Microtox® BT nano-optofluidic chip surface with Affimer® reagents (“Avacta Group”)iv and Optimers (“Aptamer Group”)v together the (“Binding Agents”).
https://www.rns-pdf.londonstockexchange.com/rns/6108S_1-2021-3-17.pdf
Daewoong Pharmaceutical and Apicel Therapeutics, a subsidiary of Daewoong Pharmaceutical, announced on the 8th that they had signed an MOU with Seoul National University Hospital to establish a regenerative medical infrastructure and cooperate in clinical research on advanced biopharmaceuticals.
Through this MOU, these three companies will ? Mutual cooperation to attract domestic and foreign research projects ? Mutual cooperation for intellectual property discovery, preservation and industrialization ? Establishment of world-class competitive regenerative medical infrastructure and Mutual cooperation in clinical research and development of advanced biopharmaceuticals ? Research We plan to cooperate with each other in matters that require cooperation, such as information provision and consulting related to development and technology exchange, education of research personnel, and mutual exchange.
Daewoong Pharmaceutical predicted that cooperation with Seoul National University Hospital would accelerate the development of advanced biopharmaceuticals in cooperation with Apicell Therapeutics. Daewoong Pharmaceutical received approval from the Ministry of Food and Drug Safety last year and entered the advanced biopharmaceutical consignment development and production business.
Apicell Therapeutics is a joint venture (JV) established jointly by Daewoong Pharmaceutical and Avacta in the UK. It is developing next-generation cell therapy products.
Daewoong Pharmaceutical CEO Jeon Seung-ho said, “I am reassured that we can work together with Seoul National University Hospital in the fields of regenerative medicine and advanced biopharmaceuticals, which are representative future industries in the pharmaceutical and medical fields. We will contribute to raising the
Seoul National University Hospital Director Kim Yeon-soo said, “I am delighted to be able to borrow the R&D capabilities of Daewoong Pharmaceutical and Apicell Therapeutics in the pharmaceutical and bio fields. I will speed up,” he said.
https://affyxell-com.translate.goog/bbs/?so_table=news&mode=VIEW&num=16&category&findType&findWord&sort1&sort2&page=1&_x_tr_sch=http&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en-US&_x_tr_pto=wapp
Therapeutics ?Apicell Therapeutics is a next-generation cell gene therapy development company. Based on Daewoong Pharmaceutical's mesenchymal stem cell platform 'DW-MSC' technology, 'Affimer' is a fusion of Avacta's Affimer platform technology, a type of non-immunoglobulin scaffold protein, to strengthen immune regulation function. Cell (AffyXell) is developed.
Both companies' technologies have overcome existing limitations. 'DW-MSC' overcomes the short lifespan and productivity limitations of existing adult tissue-derived mesenchymal stem cells, and 'Apimer' plays the same role as an antibody, but has advantages in tissue storage due to its low price and small size. The goal is to develop a therapeutic agent for diseases related to immunity and inflammation with a clear mechanism of action by synergizing the immunomodulatory function of DW-MSC and the target activation control function of Apimer.
-The meaning (background) of the company name is
?AffyXell is the name of the company as well as the name of the treatment platform to be developed. The word Affy means 'trust, betrothed' and broadly means fusion. X represents the chromosomes in our body and means the development of new cells through genetic modification. By using X instead of C in Cell, it contains the will to create a new cell therapy product that has never been before by introducing a gene with a specific function.
-If there is a company with the closest business model.
? Stem cells are developing mesenchymal stem cells, which have excellent immunomodulatory functions, as therapeutic agents that mainly target immune diseases. Domestic related companies include Daewoong Pharmaceutical, Medipost, Green Cross Lab Cell, Kang Stem Biotech, SCM Life Sciences, and CHA Biotech. Recently, in the field of immune diseases, the development of therapeutics using 'CAR-Treg', which introduces a CAR gene into regulatory T cells, is also in progress.
- Please explain the current status of pipeline development.
?The first pipeline (AFX001) is developing a treatment for organ transplant rejection and graft-versus-host disease. We confirmed the final excellent drug apimer capable of exhibiting antagonistic action against mouse and human target proteins, and introduced it into DW-MSC to construct the apicell cell line. We are accelerating the production of samples and related R&D in order to start the evaluation of efficacy in in vivo experiments on the established cell lines within this year. It plans to complete preclinical trials in 2023 and apply for IND for phase 1 clinical trials in the second half of that year. It is also aiming to conclude a license out contract before the phase 1 clinical trial of AFX001 is completed.
-You completed Series A funding in February of this year. The additional funding plan is
?First of all, attracting 8 billion won in Series A investment is the biggest achievement this year. It laid a solid foundation for technology development, a
Looking to hire
https://www-jobkorea-co-kr.translate.goog/Recruit/GI_Read/37235252?Oem_Code=C1&logpath=1&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp
Imagine waking up RNS takeover bid .. it is a strong possibility IMHO … All the big Pharma’s won’t wait till June when the price will command many multiples … Not a ramp it’s real … what Odds would a bookie give knowing that it works … and probability of failure minimal … AS stated our partnerships are going Extremely Well Hmmmmm
Our new Revised Test couldn't come sooner :
only three products for which the Agency had completed its desktop review listed on the CTDA register for approved products. Additionally, the UK Health Security Agency has published a temporary protocol which lists 48 tests (both PCR and antigen based) which passed the Public Health England validation process at Porton Down earlier in the year that can remain available for sale in the UK whilst their validation is completed until a cut-off date of 28 February 2022.